Biotech News

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Scholar Rock (SRRK)Scholar Rock2026-02-10 13:00 ESTEarnings

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 10, 2026-- Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock

Scholar Rock

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal...

Recent company news

SRRKScholar Rock2026-08-21 13:06 EST

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

SRRKScholar Rock2026-08-14 20:15 EST

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRRKScholar Rock2026-08-07 20:20 EST

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

SRRKScholar Rock2026-08-06 11:00 EST

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-07-29 12:00 EST

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Stock data

Close: 56.50 USD
Market cap: 5.35B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States